References
Dunn CJ, Spencer CM. Recombinant factor VIIa. BioDrugs 1999 Jul; 12 (1): 71–7
Shapiro AD. Recombinant factor VIIa. A viewpoint. BioDrugs 1999 Jul; 12 (1): 78
ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1999–2000. London: Datapharm Publications Ltd
AHFS Drug Information. Bethesda: American Society of Hospital Pharmacists, 1999: 1275–9, 1285–9
1999 Mosby’s GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1998: II–143–4
Mølskov Bech R. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis 1996; 26 Suppl 1: 135–8
Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998 Nov; 80: 773–8
Lusher JM. Recombinant factor VIIa (NovoSeven®) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996 Jan; 26 Suppl. 1: 124–30
Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treat-ment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia 1998; 4: 790–8
Arkin S, Cooper HA, Hutter JJ, et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Haemostasis 1998; 28: 93–8
Ingerslev J, Freidman D, Gastineau D, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996 Jan; 26 Suppl. 1: 118–23
Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998 Dec; 80: 912–8
Laurian Y, Goudemand J, Négrier C, et al. Use of recombinant activated factor VII as first-line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul Fibrinolysis 1998 Mar; 9 Suppl. 1: S155–6
Ingerslev J, Thykjaer H, Scheibel E. Approaches towards successful home treatment in patients with inhibitors. Eur J Haematol 1998; 61 Suppl. 63: 11–4
Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis 1998 Mar; 9 Suppl. 1: S119–23
Lusher JM. Recombinant factor VIIa. A viewpoint. BioDrugs 1999 Jul; 12 (1): 78–9
Schulman S. Safety, efficacy and lessons from continuous infusion with rFVIIA. Haemophilia 1998 Jul; 4: 564–7
Rights and permissions
About this article
Cite this article
Recombinant factor VIIa stops bleeding in patients with inhibitors to clotting factors. Drugs Ther. Perspect 15, 1–4 (2000). https://doi.org/10.2165/00042310-200015050-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200015050-00001